Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported R&D Expense of $125.5 thousand for fiscal year 2023.
AXIM BIOTECHNOLOGIES, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $125.5K | -18.3% |
| 2022 | $153.7K | -46.0% |
| 2021 | $284.9K | -86.1% |
| 2018 | $2.06M | +52.0% |
| 2017 | $1.35M | +474.3% |
| 2016 | $235.6K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2024 | $4.1K | -88.1% | -73.8% |
| March 31, 2024 | $15.5K | -23.8% | -55.4% |
| September 30, 2023 | $34.7K | +16.8% | +1.9% |
| June 30, 2023 | $34.1K | -3.1% | +67.6% |
| March 31, 2023 | $20.3K | -54.0% | -31.6% |
| September 30, 2022 | $29.7K | -55.8% | -15.5% |
| June 30, 2022 | $35.2K | -26.8% | -20.4% |
| March 31, 2022 | $44.2K | -56.2% | -34.3% |
- AXIM BIOTECHNOLOGIES, INC. showed a decrease of -18.3% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2023 period, AXIM BIOTECHNOLOGIES, INC.’s r&d expense has declined by 46.7% (from $235.6 thousand to $125.5 thousand).
- The most recent figure is from AXIM BIOTECHNOLOGIES, INC.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 16, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: